Skip to content
MarketNewsAPI
Product Live news Screener Coverage Pricing
Docs Overview REST API WebSocket API MCP server
Resources Use cases Blog Changelog Status Compare Contact
Log in Get API key Dashboard
JAN$28.90-1.15(-3.83%)BUZZ-Janus Living falls on upsized $748 mln equity raise8:51:45 AM ETMU$755.50-39.96(-5.02%)How Worried Should Investors Be About Micron Right Now?8:45:37 AM ETVST$117.05-3.25(-2.70%)Vistra Cratered by 25% This Year: One Wall Street Team Says 110% Returns Ahead for Investors8:45:31 AM ETBA$177.39+0.40(+0.23%)Updating The Non-Correlateds: Boeing And IBM Trying To Become Relevant Again8:45:00 AM ETQCOM$152.76-20.43(-11.80%)Qualcomm Sinks 11% as Soft Profit Guidance and Handset Slump Overshadow Beat; Arm Holdings Drops 7%, Skyworks Slides 2%8:43:59 AM ETAMZN$271.16+5.13(+1.93%)Amazon: An Earnings Supercycle Is Taking Shape8:38:41 AM ETNVDA$197.20-3.09(-1.54%)Chinese AI lab Moonshot turned to Europe for Nvidia Blackwell access amid U.S. China curbs, sources tell CNBC8:34:14 AM ETHRL$22.98+0.22(+0.97%)3 Dividend Aristocrats Trading Below Their Historical Valuations8:34:12 AM ETTSM$384.84-10.78(-2.72%)TSMC's AI Opportunity Is Expanding. Here's the Question That Matters for Its Stock Price8:33:37 AM ETHD$359.57+4.13(+1.16%)Three Days, 36 Hands-On Workshop Sessions and HGTV's Biggest Stars: Here's What's Happening Each Day at the First-Ever DIY CON November 6-88:33:00 AM ETMCD$281.60+1.38(+0.49%)McDonald's Q3: 11% EPS Growth And A 50% Operating Margin Say The Sell-Off Was A Mistake8:30:51 AM ETTMO$711.10+4.94(+0.70%)Thermo Fisher Scientific Introduces Value-Priced Thermo Scientific™ AmpSure™ Universal qPCR Master Mixes Without Compromising Performance8:30:16 AM ETAAPL$353.50+3.99(+1.14%)Apple Stock Is Up 22%, but 1 Slowing Business Could Test That Valuation8:30:00 AM ETBRK-A$881,000.00+11,699.24(+1.35%)Two in three US-listed companies pay no dividend, a census of SEC filings finds8:30:00 AM ETTEAD$0.20-0.07(-25.93%)Ad platform Teads misses Q3 revenue estimates; suspends guidance8:29:01 AM ETC$126.42+1.65(+1.32%)UPDATE 6-Oil rises as investors weigh uncertainties around Iran war8:27:07 AM ETMCD$281.60+1.38(+0.49%)McDonald's To Rally Around 9%? Here Are 10 Top Analyst Forecasts For Thursday8:22:06 AM ETMRNA$256.50-1.84(-0.71%)Moderna, Humana and Elanco Earnings Previews: What Investors Should Watch8:18:32 AM ETQCOM$152.76-20.43(-11.80%)Qualcomm: The AI Boom's Biggest Casualty8:18:20 AM ETAMD$460.24-28.54(-5.84%)AMD: The Bigger Earnings Opportunity Starts In 20278:17:47 AM ETV$440.30+3.71(+0.85%)Visa Just Raised Its Dividend 16%. Is It a Better Buy Than Mastercard?8:17:32 AM ETCVS$80.66+0.67(+0.84%)RPT-BREAKINGVIEWS-CVS’s problem: investors trust the warning label8:16:38 AM ETCOP$138.50+1.56(+1.14%)STAK Energy Signs Long-Term Agreement to Bring North Slope Natural Gas to Market8:15:00 AM ETMU$755.50-39.96(-5.02%)Is Micron stock a Buy after crashing below $800?8:13:57 AM ET

DWTX · NASDAQ

Dogwood Therapeutics, Inc.

$1.17 +0.14 (+13.59%)

Company overview

Dogwood Therapeutics, Inc., a development-stage biotechnology company, focuses on developing novel antiviral therapies to treat diseases associated with a virus-triggered abnormal immune response. The company's lead development candidate is IMC-1, a fixed-dose combination of famciclovir and celecoxib for the treatment of fibromyalgia. It is also developing IMC-2, a combination of valacyclovir and celecoxib for managing the fatigue, sleep, attention, pain, autonomic function, and anxiety associated with long COVID. The company was formerly known as Virios Therapeutics, Inc. and changed its name to Dogwood Therapeutics, Inc. in October 2024. Dogwood Therapeutics was founded in 2012 and is headquartered in Alpharetta, Georgia.

Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Market cap
$39.8M
Employees
12
Headquarters
Alpharetta, GA
Website
dwtx.com
CEO
Gregory Duncan
Listed
December 17, 2020
P/E
-0.11
Dividend yield
0.00%

Company financials

Revenue
$0.00
Gross profit
$0.00
Operating income
-$28.6M
EBITDA
-$28.5M
Net income
-$28.3M
EPS
-$10.60
Total assets
$95.2M
Total debt
$144,930
Earnings yield
-905.98%

Price chart

0.831.341.852.362.88
DWTX 1D NASDAQ O1.04H1.10L1.01C1.03-0.01 (-0.96%)Vol120.08K

News

15-min delaySigned-out view is delayed 15 minutes. Log in on Pro for the live news desk.

Start 7-day free trial See live plans
Source
Date
Type
View
Ticker Type Headline Source Published
DWTXDogwood Therapeutics, Inc. Press release Dogwood Therapeutics Announces Third Quarter 2026 Financial Results GlobeNewswire
DWTXDogwood Therapeutics, Inc. Stock news BRIEF-Dogwood Therapeutics - Files For Resale Of Up To 4,098,360 Common Shares - SEC Filing Reuters
DWTXDogwood Therapeutics, Inc. Press release Dogwood Announces $5 Million Private Placement with CK Life Sciences Int’l., (Holdings) Inc. GlobeNewswire
DWTXDogwood Therapeutics, Inc. Press release Dogwood to Participate in the 2026 Maxim Growth Summit GlobeNewswire
DWTXDogwood Therapeutics, Inc. Press release Dogwood Announces Completion of Enrollment in Ongoing Halneuron® Phase 2b Trial GlobeNewswire
DWTXDogwood Therapeutics, Inc. Stock news Dogwood Therapeutics, Inc. (DWTX) Discusses Halneuron and Pipeline Advances for Chemotherapy-Induced Neuropathic Pain Transcript Seeking Alpha
DWTXDogwood Therapeutics, Inc. Stock news Dogwood Therapeutics Nears Phase 2b Readout for Halneuron Neuropathic Pain Treatment MarketBeat
DWTXDogwood Therapeutics, Inc. Press release Dogwood Therapeutics Announces Second Quarter 2026 Financial Results GlobeNewswire
DWTXDogwood Therapeutics, Inc. Stock news Dogwood Therapeutics (NASDAQ:DWTX) Shares Up 4.3% – What’s Next? Defense World
DWTXDogwood Therapeutics, Inc. Press release Dogwood Enrolls First 200 Patients in Ongoing Halneuron® Phase 2b Chemotherapy Induced Neuropathy Trial; Top-line Data Expected in Fall 2026 GlobeNewswire
DWTXDogwood Therapeutics, Inc. Press release Dogwood Therapeutics Announces Commencement of Halneuron® Chemotherapy Induced Neuropathic Pain Phase 2b Long Term Extension Study GlobeNewswire
DWTXDogwood Therapeutics, Inc. Press release Dogwood Therapeutics Announces First Quarter 2026 Financial Results GlobeNewswire
DWTXDogwood Therapeutics, Inc. Press release Dogwood Therapeutics to Report First Quarter 2026 Financial Results on Thursday, May 14, 2026 GlobeNewswire
DWTXDogwood Therapeutics, Inc. Press release Dogwood Therapeutics Announces Worldwide Development and Commercialization Partnership for Anti-Viral Assets with Potential Value up to $100M GlobeNewswire
DWTXDogwood Therapeutics, Inc. Press release Dogwood Therapeutics Announces FDA Acceptance of SP16 Investigational New Drug Application for the Treatment of Chemotherapy Induced Pain and Neuropathy GlobeNewswire
DWTXDogwood Therapeutics, Inc. Stock news Analyzing REGENXBIO (NASDAQ:RGNX) and Dogwood Therapeutics (NASDAQ:DWTX) Defense World
DWTXDogwood Therapeutics, Inc. Stock news Dogwood Therapeutics (DWTX) to Release Quarterly Earnings on Monday Defense World
DWTXDogwood Therapeutics, Inc. Press release Dogwood Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results GlobeNewswire
DWTXDogwood Therapeutics, Inc. Stock news Dogwood Therapeutics (NASDAQ:DWTX) Shares Up 1.7% – Time to Buy? Defense World
DWTXDogwood Therapeutics, Inc. Press release Dogwood Therapeutics Announces 50% Enrollment in Ongoing Halneuron® Phase 2b Trial, Top Line Results Anticipated in Q3 2026 GlobeNewswire
See more
FAQ

Questions about Dogwood Therapeutics, Inc.

What does Dogwood Therapeutics, Inc. do?
Dogwood Therapeutics, Inc., a development-stage biotechnology company, focuses on developing novel antiviral therapies to treat diseases associated with a virus-triggered abnormal immune response. The company's lead development candidate is IMC-1, a fixed-dose combination of famciclovir and celecoxib for the treatment of fibromyalgia. It is also developing IMC-2, a combination of valacyclovir and celecoxib for managing the fatigue, sleep, attention, pain, autonomic function, and anxiety associated with long COVID. The company was formerly known as Virios Therapeutics, Inc. and changed its name to Dogwood Therapeutics, Inc. in October 2024. Dogwood Therapeutics was founded in 2012 and is headquartered in Alpharetta, Georgia.
What is DWTX's market cap?
Dogwood Therapeutics, Inc. (DWTX) is a listed stock with a live quote. The latest market cap on this page is $39.8M.
Where is Dogwood Therapeutics, Inc. headquartered?
Dogwood Therapeutics, Inc. is headquartered in Alpharetta, GA.
How do I get DWTX news from the API?
Call GET /v1/news?tickers=DWTX. Add type=news, type=press_release, or type=legal to take one feed. Pro keys search articles since 2020 in real time. Free keys are delayed 15 minutes and return the last year. Signed-out visitors and Free accounts see that same year on this page. Pro sees articles since 2020.
How far back does DWTX news go?
Signed-out visitors and Free accounts see the last year of stock news, press releases, and legal notices for DWTX, 15 minutes behind, and each headline links to the publisher. Pro, including the 7-day trial, sees articles since 2020 as headlines are ingested. A Free API key returns the last year. Pro keys search articles since 2020.
Is the DWTX price on this page from the API?
The price and daily change update during the US session for every visitor. That quote is context on this page. It is not part of the news API. The chart is one candle per session from the start of 2020. 1W, 1M, and 1Y group those sessions.
Can I use the Pro plan commercially?
No. The Pro plan cannot be used for commercial work. A product you sell, work you do for a client, or redistribution of the feed needs a custom plan and a license. Email [email protected].

Real-time stock news for $15 a month.

Start a 7-day Pro trial. A card is required. REST, WebSocket, and MCP are included, with 250 REST requests a day, 1 WebSocket connection, 5 requests per second, and 2,500 WebSocket messages a day. You won't be charged during the trial. Unless you cancel, the card is billed for Pro when it ends.

Start 7-day free trial Read the docs